A four-drug regimen for newly diagnosed high-risk multiple myeloma induced high rates of sustained minimal residual disease (MRD) negativity regardless of transplant status, a German resea… Read More
Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy for pati… Read More
Incorporating quizartinib into standard treatment for newly diagnosed acute myeloid leukemia (AML) followed by maintenance therapy with the investigational FLT3 inhibitor improved survival… Read More
BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition
, /PRNewswire/ -- Gracell Bi… Read More
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) is forging its own pathway in treating underserved diseases. And, for cancer patients, especially those resistant to or untreatable by current… Read More
Multiple myeloma (MM) is a malignant disease of the bone marrow characterized by clonal expansion of plasma cells (1, 2). Current guidelines recommend that newly diagnosed transplant-eligibl… Read More
Evaluating myeloma patients after treatment with more sensitive testing to see how much disease is left is called a minimal residual disease (MRD) test. Patients who achieve MRD negativity t… Read More
Photo courtesy of Dr. Prashant Kapoor According to recent studies, patients with multiple myeloma who achieve minimal residual disease negativity after treatment have better long-term s… Read More